Findings

What do systematic reviews say?

3,372 questions · 3,874 findings · 666 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 431 · 11.1%GRADE not reported 783 · 20.2%Very low 995 · 25.7%Low 909 · 23.5%Moderate 596 · 15.4%High 160 · 4.1%

Intervention not reported

Decrease in systolic blood pressure (mmHg) · alcohol consumers with high blood pressure

1 finding from 1 review

Alcohol intake reduction for controlling hypertension 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 269 participants
Very low

Intervention not reported

Decrease in diastolic blood pressure (mmHg) · alcohol consumers with high blood pressure

1 finding from 1 review

Alcohol intake reduction for controlling hypertension 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 269 participants
Low

Intervention not reported

Decrease in alcohol intake (g) · alcohol consumers with high blood pressure

1 finding from 1 review

Alcohol intake reduction for controlling hypertension 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 269 participants
Low

Intervention not reported

Proportion of subjects with SBP < 140 mmHg and DBP < 90 mmHg · alcohol consumers with high blood pressure

It is very uncertain whether the intervention changes proportion of subjects with SBP < 140 mmHg and DBP < 90 mmHg (very low certainty).

1 finding from 1 review

Alcohol intake reduction for controlling hypertension 2020 · Cochrane Headline outcomes only
RR 1.21 [0.88, 1.65]
1 study · 269 participants
Very low

Alirocumab vs placebo

CVD · people at high risk of CVD (history of CVD or high LDL‐C despite treatment)

Alirocumab leads to lower CVD compared with placebo (high certainty).

1 finding from 1 review

PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease 2020 · Cochrane Headline outcomes only
OR 0.87 [0.8, 0.94]
10 studies · 23868 participants
High

Alirocumab vs ezetimibe and statins

All‐cause mortality · people at high risk of CVD (history of CVD or high LDL‐C despite treatment)

Alirocumab showed no clear difference in all‐cause mortality compared with ezetimibe and statins (low certainty).

1 finding from 1 review

PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease 2020 · Cochrane Headline outcomes only
OR 0.51 [0.18, 1.4]
5 studies · 1733 participants
Low

Alirocumab vs ezetimibe and statins

Myocardial infarction · people at high risk of CVD (history of CVD or high LDL‐C despite treatment)

Alirocumab showed no clear difference in myocardial infarction compared with ezetimibe and statins (low certainty).

1 finding from 1 review

PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease 2020 · Cochrane Headline outcomes only
OR 1.45 [0.64, 3.28]
5 studies · 1734 participants
Low

Alirocumab vs ezetimibe and statins

Stroke · people at high risk of CVD (history of CVD or high LDL‐C despite treatment)

Alirocumab showed no clear difference in any stroke compared with ezetimibe and statins (low certainty).

1 finding from 1 review

PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease 2020 · Cochrane Headline outcomes only
OR 0.85 [0.13, 5.61]
5 studies · 1734 participants
Low

Evolocumab vs ezetimibe and statins

CVD · people at high risk of CVD (history of CVD or high LDL‐C despite treatment)

It is very uncertain whether evolocumab changes CVD compared with ezetimibe and statins (very low certainty).

1 finding from 1 review

PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease 2020 · Cochrane Headline outcomes only
OR 0.66 [0.14, 3.04]
1 study · 218 participants
Very low

Evolocumab vs ezetimibe and statins

All‐cause mortality · people at high risk of CVD (history of CVD or high LDL‐C despite treatment)

It is very uncertain whether evolocumab changes all‐cause mortality compared with ezetimibe and statins (very low certainty).

1 finding from 1 review

PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease 2020 · Cochrane Headline outcomes only
OR 0.43 [0.14, 1.3]
3 studies · 5223 participants
Very low

Evolocumab vs ezetimibe and statins

Myocardial infarction · people at high risk of CVD (history of CVD or high LDL‐C despite treatment)

It is very uncertain whether evolocumab changes myocardial infarction compared with ezetimibe and statins (very low certainty).

1 finding from 1 review

PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease 2020 · Cochrane Headline outcomes only
OR 0.66 [0.23, 1.85]
3 studies · 5003 participants
Very low

Evolocumab vs ezetimibe and statins

Stroke · people at high risk of CVD (history of CVD or high LDL‐C despite treatment)

1 finding from 1 review

PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease 2020 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 3899 participants
GRADE not reported

Alirocumab vs placebo

All‐cause mortality · people at high risk of CVD (history of CVD or high LDL‐C despite treatment)

Alirocumab leads to lower all‐cause mortality compared with placebo (high certainty).

1 finding from 1 review

PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease 2020 · Cochrane Headline outcomes only
OR 0.83 [0.72, 0.96]
12 studies · 24797 participants
High

Alirocumab vs placebo

Myocardial infarction · people at high risk of CVD (history of CVD or high LDL‐C despite treatment)

Alirocumab leads to lower myocardial infarction compared with placebo (high certainty).

1 finding from 1 review

PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease 2020 · Cochrane Headline outcomes only
OR 0.86 [0.79, 0.94]
9 studies · 23352 participants
High

Alirocumab vs placebo

Stroke · people at high risk of CVD (history of CVD or high LDL‐C despite treatment)

Alirocumab leads to lower any stroke compared with placebo (high certainty).

1 finding from 1 review

PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease 2020 · Cochrane Headline outcomes only
OR 0.73 [0.58, 0.91]
8 studies · 22835 participants
High

Evolocumab vs placebo

CVD · people at high risk of CVD (history of CVD or high LDL‐C despite treatment)

Evolocumab leads to lower CVD compared with placebo (high certainty).

1 finding from 1 review

PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease 2020 · Cochrane Headline outcomes only
OR 0.84 [0.78, 0.91]
3 studies · 29432 participants
High

Evolocumab vs placebo

All‐cause mortality · people at high risk of CVD (history of CVD or high LDL‐C despite treatment)

Evolocumab showed no clear difference in all‐cause mortality compared with placebo (high certainty).

1 finding from 1 review

PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease 2020 · Cochrane Headline outcomes only
OR 1.04 [0.91, 1.19]
3 studies · 29432 participants
High

Evolocumab vs placebo

Myocardial infarction · people at high risk of CVD (history of CVD or high LDL‐C despite treatment)

Evolocumab leads to lower myocardial infarction compared with placebo (high certainty).

1 finding from 1 review

PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease 2020 · Cochrane Headline outcomes only
OR 0.72 [0.64, 0.82]
3 studies · 29432 participants
High

Evolocumab vs placebo

Stroke · people at high risk of CVD (history of CVD or high LDL‐C despite treatment)

Evolocumab leads to lower any stroke compared with placebo (high certainty).

1 finding from 1 review

PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease 2020 · Cochrane Headline outcomes only
OR 0.79 [0.65, 0.94]
2 studies · 28531 participants
High

Alirocumab vs ezetimibe and statins

CVD · people at high risk of CVD (history of CVD or high LDL‐C despite treatment)

Alirocumab showed no clear difference in CVD compared with ezetimibe and statins (low certainty).

1 finding from 1 review

PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease 2020 · Cochrane Headline outcomes only
OR 1.37 [0.65, 2.87]
3 studies · 1379 participants
Low